These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 31160357

  • 1. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
    Pagan C, Barua S, Hsiao SJ, Mansukhani M, Saqi A, Murty V, Fernandes H.
    Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
    [Abstract] [Full Text] [Related]

  • 2. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T, Chen Z, Gu J, Wang Y, Zhang J, Min L.
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [Abstract] [Full Text] [Related]

  • 3. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 4. Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.
    Wu X, Wang W, Zou B, Li Y, Yang X, Liu N, Ma Q, Zhang X, Wang Y, Li D.
    Thorac Cancer; 2020 Jun; 11(6):1695-1698. PubMed ID: 32212216
    [Abstract] [Full Text] [Related]

  • 5. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
    Gao F, Gao F, Wu H, Lu J, Xu Y, Zhao Y.
    Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
    [Abstract] [Full Text] [Related]

  • 6. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G, Pajor G, Szuhai K, Morreau H, Kocsmár I, Kocsmár É, Pajor L, Kajtár B, Sárosi V, Lotz G, Tornóczky T.
    Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
    [Abstract] [Full Text] [Related]

  • 7. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H, Liu Y, Wang W, Tang Y, Tian P, Li W.
    Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
    [Abstract] [Full Text] [Related]

  • 8. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C, Tang Y, Li Y, Chen Y, Tian P, Wang Y, Gong Y, Peng F, Zhang Y, Yu M, Wang K, Zhu J, Lu Y, Huang M.
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
    Tao H, Liu Z, Mu J, Gai F, Huang Z, Shi L.
    Diagn Pathol; 2022 Feb 10; 17(1):27. PubMed ID: 35144623
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib.
    Guo W, Liang J, Zhang D, Huang X, Lv Y.
    Medicine (Baltimore); 2022 Oct 07; 101(40):e30913. PubMed ID: 36221356
    [Abstract] [Full Text] [Related]

  • 14. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
    Xia H, Liang B, Liu G, Qi Y, Luo N, Li M.
    Medicine (Baltimore); 2022 Apr 08; 101(14):e29134. PubMed ID: 35446297
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M, Wang Q, Ding Y, Wang G, Chu Y, He X, Wu X, Shao YW, Lu K.
    J Thorac Oncol; 2018 Nov 08; 13(11):1792-1797. PubMed ID: 30010043
    [Abstract] [Full Text] [Related]

  • 17. Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.
    Luo J, Gu D, Lu H, Liu S, Kong J.
    J Thorac Oncol; 2019 Dec 08; 14(12):e266-e268. PubMed ID: 31757376
    [No Abstract] [Full Text] [Related]

  • 18. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y, Kacal M, Kanony M, Stukan I, Jatta K, Kis L, Norberg E, Vakifahmetoglu-Norberg H, Lewensohn R, Hydbring P, Ekman S.
    Biochem Biophys Res Commun; 2019 Apr 02; 511(2):260-265. PubMed ID: 30791979
    [Abstract] [Full Text] [Related]

  • 19. A novel GHR-ALK fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report.
    Pan X, Zhong A, Xing Y, Li X, Du H, Shi M.
    J Int Med Res; 2021 Sep 02; 49(9):3000605211044652. PubMed ID: 34590916
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.